NVS - Novartis wins pediatric indication for Lutathera for rare cancer
2024-04-23 14:08:57 ET
More on Novartis
- Novartis AG (NVS) Q1 2024 Earnings Call Transcript
- Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results
- Novartis AG 2024 Q1 - Results - Earnings Call Presentation
- Biggest stock movers today: SPOT, GM, DHR, IBRX, NVS, and more
- Novartis beats top-line and bottom-line estimates; raises FY24 outlook